[go: up one dir, main page]

ES2164011A1 - Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors - Google Patents

Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors

Info

Publication number
ES2164011A1
ES2164011A1 ES200000459A ES200000459A ES2164011A1 ES 2164011 A1 ES2164011 A1 ES 2164011A1 ES 200000459 A ES200000459 A ES 200000459A ES 200000459 A ES200000459 A ES 200000459A ES 2164011 A1 ES2164011 A1 ES 2164011A1
Authority
ES
Spain
Prior art keywords
substances
chemokine
interleukin
treatment
tumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200000459A
Other languages
Spanish (es)
Other versions
ES2164011B1 (en
Inventor
Cuervas-Mons Inigo Narvaiza
Rizzo Guillermo Mazzolini
Bermejo Ignacio Melero
Cheng Qian
Valtuena Jesus Prieto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES200000459A priority Critical patent/ES2164011B1/en
Priority to PCT/ES2001/000066 priority patent/WO2001062274A1/en
Priority to AU2001233811A priority patent/AU2001233811A1/en
Publication of ES2164011A1 publication Critical patent/ES2164011A1/en
Application granted granted Critical
Publication of ES2164011B1 publication Critical patent/ES2164011B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns the combined use of chemokine IP-10 and interleukin 12 as therapy against malignant tumors and the use of IP-10 to potentiate the anti-tumoral effect of IL-12. Said substances are immunomodulating proteins enhancing anti-tumoral response. Combined administration of both substances to mammals makes it possible to enhance anti-tumoral activity in the tumor carrying mammal. Administration of both substances can be realized by means of a recombinant protein prepared in-vitro or by means of expression systems or gene transfer expressing said substances. The combination of both substances has a synergistic effect in the specific induction of cytotoxic lymphocytes against tumors. Combination of both substances in adequate proportions and dose can be useful in the treatment of any type of cancer, for instance adenocarcinoma of the colon.
ES200000459A 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. Expired - Lifetime ES2164011B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200000459A ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.
PCT/ES2001/000066 WO2001062274A1 (en) 2000-02-25 2001-02-22 Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors
AU2001233811A AU2001233811A1 (en) 2000-02-25 2001-02-22 Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000459A ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.

Publications (2)

Publication Number Publication Date
ES2164011A1 true ES2164011A1 (en) 2002-02-01
ES2164011B1 ES2164011B1 (en) 2003-05-16

Family

ID=8492479

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200000459A Expired - Lifetime ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.

Country Status (3)

Country Link
AU (1) AU2001233811A1 (en)
ES (1) ES2164011B1 (en)
WO (1) WO2001062274A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. Identification of bacteria for cancer therapy

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
JP2006515619A (en) * 2003-01-07 2006-06-01 チルドレンズ ホスピタル メディカル センター Eosinophil cytokine inhibition
MX2017013321A (en) 2015-04-22 2018-07-06 Curevac Ag Rna containing composition for treatment of tumor diseases.
HUE061077T2 (en) 2016-05-18 2023-05-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
JP6949131B2 (en) 2017-02-28 2021-10-13 サノフイＳａｎｏｆｉ Therapeutic RNA
JP7285220B2 (en) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006759A2 (en) * 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006759A2 (en) * 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUDA, D.G. et al. "Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of Interleukin 12". CANCER RESEARCH. Volumen 60, no 4, 15.02.2000, paginas 1111-1116, todo el documento. *
LODE, H.N. et al. "CXC chemokine IP-10 mediated IL-12 gene therapy induced T-cell memory immune response is amplified by targeted IL-2". EUROPEAN JOURNAL OF CANCER. Volumen 35, No SUPPL. 5, octubre 1999, pagina 551, resumen. *
NANNI, P. et al. "Interleukin 12 gene therapy of MHC-negative murine melanoma metastases". CANCER RESEARCH. Volumen 58, no 6, 15.03.1998, paginas 1225-1230, todo el documento. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. Identification of bacteria for cancer therapy

Also Published As

Publication number Publication date
ES2164011B1 (en) 2003-05-16
WO2001062274A1 (en) 2001-08-30
AU2001233811A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
Iigo et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors
BR9407956A (en) Pharmaceutical composition vector of recombinant adenovirus expression and kit to reduce tumor cell proliferation
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
MXPA03010121A (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents.
EP0256714A3 (en) Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
NZ500657A (en) Interleukin-3 gene therapy for cancer
NZ212632A (en) Tumor necrosis factor, its preparation and its use
IL146950A0 (en) Recombinant anti-cd40 antibody and uses thereof
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
Hellstrand et al. Histamine: a novel approach to cancer immunotherapy
WO2004074437A3 (en) Compositions and methods for cancer immunotherapy
IL145514A0 (en) Akt nucleic acids, polypeptides, and uses thereof
ES2164011A1 (en) Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
Teicher et al. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
EP1176870A4 (en) Tgf-alpha polypeptides, functional fragments and methods of use therefor
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
ZA200107368B (en) Immunostimulant bacterial membrane fractions in cancer treatment
ITRM960687A1 (en) IMMUNOGENIC COMPOSITION FROM TLP
AU2821000A (en) Matrix protein compositions for induction of apoptosis
IT1271688B (en) HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
Laurent et al. Interferon alpha and 5′-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
Hamasaki et al. Interferons and other cytokines in head and neck cancer

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020201

Kind code of ref document: A1

Effective date: 20020201

FG2A Definitive protection

Ref document number: 2164011B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20031120